Cargando…
Antipsychotic Drugs Opposite to Metabolic Risk: Neurotransmitters, Neurohormonal and Pharmacogenetic Mechanisms Underlying with Weight Gain and Metabolic Syndrome
Important sources of metabolic diseases such as obesity and metabolic syndrome are significantly more prevalent in patients treated with antipsychotic drugs than the general population and they not only reduce the quality of life but also significantly reduce the life expectancy, being important ris...
Autores principales: | Milano, Walter, De Rosa, Michele, Milano, Luca, Capasso, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722531/ https://www.ncbi.nlm.nih.gov/pubmed/23894259 http://dx.doi.org/10.2174/1874205X01307010023 |
Ejemplares similares
-
Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review
por: Reynolds, Gavin P.
Publicado: (2012) -
The Effects of Alcohol Intoxication and Withdrawal on Hypothalamic Neurohormones and Extrahypothalamic Neurotransmitters
por: Simon, Balázs, et al.
Publicado: (2023) -
Agomelatine Efficacy in the Night Eating Syndrome
por: Milano, Walter, et al.
Publicado: (2013) -
The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
por: Libowitz, Mark R., et al.
Publicado: (2021) -
Pharmacogenetics and outcome with antipsychotic drugs
por: Pouget, Jennie G., et al.
Publicado: (2014)